Jump to main content
Jump to site search

Issue 12, 2014
Previous Article Next Article

Structure–activity relationship studies of SETD8 inhibitors

Author affiliations

Abstract

SETD8 (also known as SET8, PR-SET7, or KMT5A (lysine methyltransferase 5A)) is the only known lysine methyltransferase that catalyzes the monomethylation of histone H4 lysine 20 (H4K20). In addition to H4K20, SETD8 monomethylates non-histone substrates such as the tumor suppressor p53 and the proliferating cell nuclear antigen (PCNA). Because of its role in regulating diverse biological processes, SETD8 has been pursued as a potential therapeutic target. We recently reported the first substrate-competitive SETD8 inhibitor, UNC0379 (1), which is selective for SETD8 over 15 other methyltransferases. We characterized this inhibitor in a battery of biochemical and biophysical assays. Here we describe our comprehensive structure–activity relationship (SAR) studies of this chemical series. In addition to 2- and 4-substituents, we extensively explored 6- and 7-substituents of the quinazoline scaffold. These SAR studies led to the discovery of several new compounds, which displayed similar potencies as compound 1 and interesting SAR trends.

Graphical abstract: Structure–activity relationship studies of SETD8 inhibitors

  • This article is part of the themed collection: Epigenetics
Back to tab navigation

Supplementary files

Publication details

The article was received on 21 Jul 2014, accepted on 16 Sep 2014 and first published on 17 Sep 2014


Article type: Concise Article
DOI: 10.1039/C4MD00317A
Author version
available:
Download author version (PDF)
Med. Chem. Commun., 2014,5, 1892-1898

  •   Request permissions

    Structure–activity relationship studies of SETD8 inhibitors

    A. Ma, W. Yu, Y. Xiong, K. V. Butler, P. J. Brown and J. Jin, Med. Chem. Commun., 2014, 5, 1892
    DOI: 10.1039/C4MD00317A

Search articles by author

Spotlight

Advertisements